TherapeuticsMD
TXMD
36 hedge funds and large institutions have $9.02M invested in TherapeuticsMD in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 10 closing their positions.
295% more call options, than puts
Call options by funds: $312K | Put options by funds: $79K
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
1.31% less ownership
Funds ownership: 29.55% → 28.24% (-1.3%)
14% less funds holding
Funds holding: 42 → 36 (-6)
28% less capital invested
Capital invested by funds: $12.5M → $9.02M (-$3.47M)
60% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
+$38.4K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$30.7K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$11.4K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$6.1K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.44K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Charles Schwab
San Francisco,
California
|
-$217K |
| 2 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$30.1K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
-$12.4K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$6.34K |
| 5 |
BlackRock
New York
|
-$2.35K |
TXMD Hedge Fund Activity: Q3 2023 in Review
36 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q3 2023, worth a combined $9.02M — down 28% from $12.5M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of TXMD and 4 opened new positions — a net loss of 6 holders — while 6 trimmed existing stakes and 7 added.
The largest buyer was Dimensional Fund Advisors, opening a new position worth an estimated $38.4K. The largest seller was Charles Schwab, exiting entirely with an estimated $217K sold.
- 36 institutional investors held TherapeuticsMD (TXMD) as of Q3 2023, down from 42 in Q2 2023.
- Funds reported $9.02M of TherapeuticsMD stock for Q3 2023, down 28% quarter-over-quarter.
- 4 funds opened new TherapeuticsMD positions in Q3 2023 and 10 closed out, a net change of -6 holders.
- The largest TherapeuticsMD buyer in Q3 2023 was Dimensional Fund Advisors, an estimated $38.4K added.
- The largest TherapeuticsMD seller in Q3 2023 was Charles Schwab, an estimated $217K sold.
Based on aggregated 13F filings for Q3 2023.